Novo being Novo

Novo being Novo

There have been many positive changes at Novo over the past few years. Yet Novo being Novo they just can’t get away from their DNA. It’s an understatement to say that things are going well, more like fantastic. Sales of Wegovy are skyrocketing, Ozempic has become the poster child for weight loss medications and has people singing that nifty jingle.

Just as the CGM market has developed into a duopoly so too has the GLP1 market and just as they fought it out in the insulin market with their archrival these two longtime rivals have just moved to . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.